NDAORALTABLET, EXTENDED RELEASE
Approved
Jun 2012
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
MYRBETRIQ (mirabegron) by Ascentage Pharma is adrenergic beta3-agonists [moa]. First approved in 2012.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Myrbetriq (mirabegron) is an oral, extended-release beta-3 adrenergic agonist approved in 2012 for overactive bladder (OAB) symptoms including urge incontinence, urgency, and frequency. It represents a novel mechanism distinct from anticholinergics, working by relaxing bladder smooth muscle during the storage phase of the urinary cycle.
$2.5BPart D
PeakStable
3.8 years to LOEMyrbetriq remains a mature, high-revenue asset at peak lifecycle with substantial Medicare utilization, supporting large commercial and medical teams but facing increasing generic/biosimilar competition pressure.
Mechanism of Action
Adrenergic beta3-Agonists
Pharmacologic Class:
beta3-Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
Started Feb 2024
7 enrolled
Neurogenic Detrusor Overactivity
Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults
Started Aug 2023
37 enrolled
Healthy
Does Mirabegron Increase the Body Heat Generated by the Nervous System
Started Apr 2023
19 enrolled
Thermoregulation
Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study
Started Jul 2022
600 enrolled
Overactive Bladder
Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)
Started May 2022
30 enrolled
Healthy
Worked on MYRBETRIQ at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.